Sanwei Doukou Decoction ameliorate plateau insomnia through the TLR4/MyD88/NF-κB signaling pathway

Authors:
  • QLQinqian Li
    Qinqian Li
  • ZLZiqi Li
    Ziqi Li
  • GHGuoting Hu
    Guoting Hu
  • HXHuanhua Xu
    Huanhua Xu
  • YCYuying Cheng
    Yuying Cheng
  • HLHuan Liang
    Huan Liang
  • PHPeng-Yi Hu
    Peng-Yi Hu

Abstract
Ethnopharmacological relevanceSanwei Doukou decoction (SDKD) is a classical Tibetan medicine widely used for plateau insomnia in clinical, yet its underlying mechanism remains unclear.Aim of the studyThis study aims to elucidate the mechanisms of SDKD in alleviating plateau insomnia, focusing on the TLR4/MyD88/NF-κB pathway.Materials and methodsChemical components of SDKD were analyzed by Gas chromatography-mass spectrometry (GC-MS). The mouse model of high-altitude insomnia was established under hypobaric hypoxia. Sleep behaviors were observed in vivo. Inflammatory cytokines and neurotransmitters were detected by ELISA. Oxidative stress markers were measured using biochemical kits. Protein expression was examined by immunohistochemistry and Western blot.ResultsSDKD significantly ameliorated plateau insomnia by shortening sleep latency and prolonging sleep duration. GC-MS identified 36 volatile oil components. SDKD reduced serum TNF-α, IL-6 and IL-1β, and increased GABA and melatonin levels in brain tissue. It also decreased MPO and MDA contents, while elevating SOD, GSH-Px and GSH activities. Immunohistochemistry showed that SDKD alleviated hypoxia-induced brain injury. Western blot revealed that SDKD suppressed overactivation of the TLR4/MyD88/NF-κB pathway and upregulated GABRA1 and GABRG2 expression.ConclusionSDKD exerts anti-insomnia effects via inhibiting inflammation through the TLR4/MyD88/NF-κB pathway, enhancing GABAergic neurotransmission, improving antioxidant capacity, and relieving hypoxic brain damage. These findings confirm the classical clinical application of this prescription in high-altitude sleep disorders.